• eCRFs were triggered randomly according to pre-defined EMR criteria ( Figure 1B ).
• The analysis of CES-D questionnaire results from the PRO patient cohort (n = 270) using a linear regression model shows a trend towards an increased depression score in patients with a shorter disease duration of T2D (< 2 years), also when adjusted according to patient age and sex ( Figure 3 ).
• Patients with the highest BMI (> 40) showed the lowest physical subscores in the SF-36 QoL questionnaire and had a significantly lower physical subscore than patients with a BMI of 25 -30 (p < 0.05) . (Figure 4) -There was no significant correlation between BMI and depression as assessed by the CES-D questionnaire.
• PROs were collected using 6 different questionnaires handed to and completed by patients during physician visits (Table 2 ). • At present, the number of people with diabetes in Germany is estimated to be 7.6 million, approximately 95 % of which suffer from type 2 diabetes (T2D) [1] .
• To evaluate therapeutic efficacy in daily clinical practice and the state of T2D patient care, noninterventional studies (e. g., registry studies) are frequently conducted [2] . Using registries, course and duration of therapy and resource expenditure from routine care can be measured and used to illustrate the real-world state of patient care [3] .
• Thus far, however, quality of life (QoL) and subjective patient well-being have frequently been neglected. Furthermore, several diabetes registries only include a limited timeframe or certain patient groups (e. g., DIVE, DiaRegis, DIALOGUE [4 -6] ). Moreover, registries based on data from routine clinical practices are frequently incomplete (e. g., data on body-mass-index [BMI] or HbA 1c ) and do not consider behavioural aspects.
Introduction
• The DIAREG T2D registry was initiated in July 2013 as part of a cooperation between AstraZeneca and IMS ® Health with guidance by a scientific advisory board.
• DIAREG is based on the combined, self-complimentary recording and processing of retrospective IMS ® Health Disease Analyzer patient data (Electronic Medical Records, EMRs) [7] and prospective data from physician questionnaires (electronic Case Report Forms, eCRFs) as well as validated patient questionnaires (Patient-Reported Outcomes, PROs) ( Figures 1A and B , Table 1 ).
• Patients included in the DIAREG registry provided informed consent on the anonymised merging* and evaluation of information obtained from EMRs, eCRFs and PRO questionnaires. The registry protocol has been approved by the ethics committee of the Medical Association of Nordrhein, Germany.
• DIAREG is registered with ClinicalTrials.gov (NCT01906294).
Methods
• By the end of June 2015 complete data for approximately 1,800 patients with T2D were available (overall cohort). These comprise an observational period of 22 months (August 2013 -June 2015 . From August 2014 until June 2015 PROs from 270 patients (PRO cohort) could be obtained.
• The baseline characteristics of patients included in DIAREG and the PRO patient cohort are shown in Table 3 .
Results
• This initial PRO subgroup analysis is cross-sectional in nature, and longitudinal analyses are required to obtain results regarding patient QoL and therapy quality or changes over the course of the disease.
Limitation
• DIAREG is a multi-dimensional registry offering a valuable opportunity to better understand the state of T2D patient care in primary and specialist practice through longitudinal evaluation of PROs and clinical outcomes.
• Future longitudinal analyses will focus on the correlation between:
-QoL, depression and quality of diabetes control (HbA 1c , hypoglycaemic events); -QoL, depression and therapy adherence;
-Change in QoL and depression after change of therapy (novel vs. classical antidiabetic drugs).
• DIAREG is the first registry in Germany reporting comprehensive subjective PRO data in combination with clinical characteristics of patients with T2D in primary and specialist care.
• Initial results from the PRO cohort show an increased depression score at a short duration of diabetes (< 2 years) and a reduced QoL in very obese patients (BMI > 40). There was no correlation between QoL and HbA 1c control and type of antidiabetic therapy. • A change in therapy since the last visit was recorded in 10 % of patients (n = 185). In 69 % of these patients (n = 128) this occurred through a dose modification; a change of medication was carried out in 31 % of patients (n = 57). Principal reason for a change of medication by the attending physician was insufficient HbA 1c reduction (Figure 2 ). 
Conclusions
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